Embecta Corp./$EMBC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Embecta Corp.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
Ticker
$EMBC
Sector
Primary listing
Industry
Health Care Equipment & Supplies
Headquarters
Employees
2,100
ISIN
US29082K1051
Website
Embecta Corp. Metrics
BasicAdvanced
$542M
10.40
$0.89
1.19
$0.60
6.47%
Price and volume
Market cap
$542M
Beta
1.19
52-week high
$21.23
52-week low
$9.25
Average daily volume
712K
Dividend rate
$0.60
Financial strength
Current ratio
2.481
Quick ratio
1.589
Long term debt to equity
-210.459
Total debt to equity
-213.067
Dividend payout ratio (TTM)
65.91%
Interest coverage (TTM)
0.38%
Profitability
EBITDA (TTM)
83.8
Gross margin (TTM)
64.06%
Net profit margin (TTM)
4.89%
Operating margin (TTM)
4.35%
Effective tax rate (TTM)
4.17%
Revenue per employee (TTM)
$510,000
Management effectiveness
Return on assets (TTM)
2.37%
Return on equity (TTM)
-7.01%
Valuation
Price to earnings (TTM)
10.402
Price to revenue (TTM)
0.498
Price to book
-0.74
Price to tangible book (TTM)
-0.71
Price to free cash flow (TTM)
13.546
Free cash flow yield (TTM)
7.38%
Free cash flow per share (TTM)
68.51%
Dividend yield (TTM)
6.47%
Forward dividend yield
6.47%
Growth
Revenue change (TTM)
-4.68%
Earnings per share change (TTM)
-26.96%
3-year revenue growth (CAGR)
-2.36%
3-year earnings per share growth (CAGR)
-48.85%
What the Analysts think about Embecta Corp.
Analyst ratings (Buy, Hold, Sell) for Embecta Corp. stock.
Bulls say / Bears say
Embecta Corp. reported a 2.7% increase in fourth-quarter fiscal year 2023 revenues, indicating positive sales momentum. (globenewswire.com)
The company successfully transitioned approximately 98% of its revenue to its own ERP system, enhancing operational efficiency. (tradingview.com)
Embecta's launch of small-pack GLP-1 needles in Germany has been successful, with plans to expand into other markets, potentially increasing market share. (tradingview.com)
Embecta discontinued its insulin patch pump program, which may limit future growth opportunities in the insulin delivery market. (nasdaq.com)
The company announced a restructuring plan expected to incur pre-tax charges between $35 million and $45 million in fiscal year 2025, potentially impacting short-term profitability. (nasdaq.com)
Embecta's fiscal year 2025 revenue guidance indicates a decline of 2.7% to 1.2%, suggesting potential challenges in maintaining revenue growth. (tradingview.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.
Embecta Corp. Financial Performance
Revenues and expenses
Embecta Corp. Earnings Performance
Company profitability
Embecta Corp. News
AllArticlesVideos
embecta to Participate in Investor Events
GlobeNewsWire·1 month ago
embecta to Showcase Phased Approach for Value Creation and Present Long Range Financial Plan at 2025 Analyst and Investor Day
GlobeNewsWire·1 month ago
Embecta Corp. Reports Second Quarter Fiscal 2025 Financial Results
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Embecta Corp. stock?
Embecta Corp. (EMBC) has a market cap of $542M as of June 27, 2025.
What is the P/E ratio for Embecta Corp. stock?
The price to earnings (P/E) ratio for Embecta Corp. (EMBC) stock is 10.4 as of June 27, 2025.
Does Embecta Corp. stock pay dividends?
Yes, the Embecta Corp. (EMBC) stock pays dividends to shareholders. As of June 27, 2025, the dividend rate is $0.6 and the yield is 6.47%. Embecta Corp. has a payout ratio of 65.91% on a trailing twelve-month basis.
When is the next Embecta Corp. dividend payment date?
The next Embecta Corp. (EMBC) dividend payment date is unconfirmed.
What is the beta indicator for Embecta Corp.?
Embecta Corp. (EMBC) has a beta rating of 1.19. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.